Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inivata Continues Trials Of Its Liquid Biopsy Platform

Executive Summary

The partnership with the Princess Margaret Cancer Center will support two studies of liquid biopsy testing for lung cancer.

You may also be interested in...



NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata

Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.

Exec Chat: Cognetivity’s Simple Brain Test Could Unlock Trillions In Health Care Savings

Cognetivity Neuroscience’s CognICA tool uses a language and education-independent approach to assess whether a patient is exhibiting cognitive decline, so it could also aid drug discovery.

Minute Insight: MeMed Announces Viral/Bacterial Infection Differentiation Results, Commercial Partnership

DiaSorin will distribute MeMed BV, a rapid point-of-care test that can differentiate bacterial and viral infections, under a new commercial agreement.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel